Pathos AI has announced strategic collaborations with Bristol Myers Squibb and Tempus AI to advance AI-driven drug development, beginning with Alzheimer's disease and other neurological conditions.
The collaborations bring together data infrastructure, artificial intelligence, and neuroscience expertise to support more informed research and development decisions and accelerate innovation for patients.
Congratulations to the Pathos team on this important milestone.
